- Home
- COLB vs ABVX Comparison
COLB vs ABVX Comparison
Compare COLB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | COLB | ABVX |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.6B |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | COLB | ABVX |
|---|---|---|
| Price | $28.94 | $92.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $33.33 | ★ $163.58 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 10-22-2026 | 09-21-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $177,000,000.00 | N/A |
| Revenue This Year | $18.98 | N/A |
| Revenue Next Year | $2.15 | $1,695.54 |
| P/E Ratio | $21.01 | ★ N/A |
| Revenue Growth | ★ 18.94 | N/A |
| 52 Week Low | $24.75 | $69.81 |
| 52 Week High | $33.68 | $148.83 |
Technical Indicators
Market Signals| Indicator | COLB | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 38.82 |
| Support Level | $26.57 | $84.11 |
| Resistance Level | $30.06 | $128.68 |
| Average True Range (ATR) | 0.55 | 3.44 |
| MACD | 0.04 | 0.67 |
| Stochastic Oscillator | 40.65 | 30.10 |
Price Performance
Historical ComparisonAbout COLB Columbia Banking System Inc.
Columbia Banking System Inc is a registered bank holding company whose wholly-owned banking subsidiary is Columbia State Bank. The company provides a full range of banking services to small and medium sized businesses, professionals, and individuals throughout Washington, Oregon, Idaho, and California. The company's subsidiary Columbia Trust Company is an Oregon trust company that provides agency, fiduciary, and other related trust services with offices in Washington, Oregon, and Idaho. The firm offers various products and services under Personal Banking, Business Banking, and Wealth Management divisions.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.